ASCO Data Supports Prophylaxis to Prevent CRS in Multiple Myeloma
New data from this week’s American Society of Clinical Oncology (ASCO) conference reveals that preemptive treatment with the interleukin-6 (IL-6) receptor antagonist tocilizumab (brand name: Actemra) significantly reduces the severity ... Read More